Celladon Corporation announces in-license of stem cell factor development program
Celladon announced an exclusive, global license from Enterprise Partners Venture Capital for gene therapy applications of membrane-bound form of the Stem Cell Factor gene for treatment of cardiac ischemia. Stem Cell Factor is a critical cytokine which contributes to survival of cardiac stem cells. July 21, 2014